Change of Significant Shareholder's Interest


 
TIDMENTL




  In accordance with Rule 17 of the AIM rules for Companies, Entelos, Inc. (LSE: ENTL) announces that on January 21, 2009 it received a notification from Imperium Master Fund, LTD ("Imperium") that Imperium acquired a total of 3,990,537 shares of Entelos' common stock in December 2008




  As a result of this acquisition, Imperium now holds 6.1% of the issued and outstanding common stock in Entelos and is, as such, a significant shareholder for the purposes of the AIM Rules for Companies.




  About Entelos




  Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, "virtual human" technology, and toxicology reference systems to develop safer and more effective drugs, improve the quality of health-related consumer products, and deliver on the promise of personalized medicine. Entelos provides customized products, technology and research services to global pharmaceutical, health-care, and consumer products companies in safety testing, arthritis, cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care products.

Entelos Regs (LSE:ENTL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024